成都先导药物开发股份有限公司 董事会审计委员会 2024 年度履职报告 根据《上海证券交易所科创板股票上市规则》、《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》以及《公司章程》、《审计委员会工作细 则》等相关规定，成都先导药物开发股份有限公司（以下简称"公司"）董事会审 计委员会认真履行审计监督职责，积极开展审计委员会工作，现对 2024 年度履 职情况报告如下： 一、董事会审计委员会基本情况 公司第二届董事会审计委员会由余海宗先生、薛军福先生、李建国先生三名 成员组成，其中余海宗先生、薛军福先生为公司独立董事。余海宗先生具有会计 专业资格，担任审计委员会主任委员，专业结构合理，符合相关法律法规要求。 二、董事会审计委员会 2024 年度会议召开情况 报告期内，公司共召开审计委员会 6 次，具体召开情况如下： | 召开日期 | | | 会议内容 | 重要意见和建议 | | --- | --- | --- | --- | --- | | 年 2024 4 | 月 | 日 23 | 议案 1-关于审议公司 年年度报告及其摘要 2023 | 审议通过以上议案 | | | | | 的议案 | 并 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-010 成都先导药物开发股份有限公司 2024 年年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求(2022 年修订)》、《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》等相关规定，本公司就 2024 年年度募 集资金存放与实际使用情况作如下专项报告： 一、 募集资金的基本情况 经中国证券监督管理委员会证监许可[2020]429 号文《关于同意成都先导药 物开发股份有限公司首次公开发行股票注册的批复》同意，成都先导药物开发股 份有限公司（以下简称"公司"或"成都先导"）于 2020 年 4 月 16 日在上海证 券交易所以每股人民币20.52元的价格公开发行40,680,000股人民币普通股(A 股) 股票，募集资金总额人民币 834,753,600.00 元，扣除发行费人民币 88,742,433.8 ...

关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 证券代码：688222 证券简称：成都先导 公告编号：2025-015 成都先导药物开发股份有限公司 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 23 日 14 点 30 分 召开地点：成都市双流区慧谷东一路 8 号天府国际生物城 C2 栋成都先导药 物开发股份有限公司二楼大会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 23 日 至2025 年 5 月 23 日 股东大会召开日期：2025年5月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过 ...

证券代码： 688222 证券简称：成都先导 公告编号：2025-007 成都先导药物开发股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 监事会认为：报告期内，公司监事会严格按照《公司法》等法律法规及《公 司章程》《监事会议事规则》等内部规章制度要求，遵守诚信原则，从切实维护 公司利益和全体股东权益出发，认真履行了监督职责。 表决情况：3 票同意，0 票反对，0 票弃权。 本议案尚需提交公司股东大会审议表决。 一、监事会会议召开情况 成都先导药物开发股份有限公司（以下简称"公司"）第二届监事会第十六次 会议于 2025 年 4 月 24 日在公司会议室以现场表决方式召开，会议通知已于 2025 年 4 月 14 日以书面方式送达全体监事。会议应出席监事 3 人，实际到会监事 3 人，公司董事会秘书与证券事务代表列席会议，会议由监事会主席徐晨晖主持。 会议的召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议决议合法、有效。 二、监事会会议审议 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-006 成都先导药物开发股份有限公司 第二届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都先导药物开发股份有限公司（以下简称"公司"）第二届董事会第二十次 会议于 2025 年 4 月 24 日在公司会议室以现场结合通讯表决方式召开，会议通知 已于 2025 年 4 月 14 日以书面方式送达全体董事。本次会议应出席董事 9 名，实 际出席董事 9 名，公司监事、董事会秘书和部分高级管理人员列席本次会议，会 议由董事长 JIN LI（李进）先生召集并主持。本次会议的召集和召开程序符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议决议合 法、有效。 二、董事会会议审议情况 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： (一) 审议通过《关于审议公司 2024 年年度报告及其摘要的议案》 (四) 审议通过《关于独立董事独立性情况评估的议案》 公司在任独立董事郭云沛、薛军 ...

每股分配比例：A 股每 10 股派发现金红利 0.6 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购 专用证券账户中的股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 公司 2024 年度利润分配方案不触及《上海证券交易所科创板股票上市 规则》（以下简称"科创板股票上市规则"）第 12.9.1 条第一款第（八）项规定的 可能被实施其他风险警示的情形。本次利润分配方案尚需提交公司 2024 年年度 股东大会审议。 一、利润分配预案内容 成都先导药物开发股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688222 证券简称：成都先导 公告编号：2025-008 重要内容提示： （一）利润分配方案的具体内容 经德勤华永会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 成都先导药物开发股份有限公司（以下 ...

成都先导药物开发股份有限公司 关于作废剩余已授予尚未归属的 2021 年限制性股票的公告 证券代码：688222 证券简称：成都先导 公告编号：2025-013 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据成都先导药物开发股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第二届董事会第二十次会议和第二届监事会第十六次会议，审议通过了 《关于作废剩余已授予尚未归属的 2021 年限制性股票的议案》等议案，现将相 关事项说明如下： 一、已履行的相关审批程序 1、2021 年 10 月 28 日，公司召开第一届董事会第十八次会议，审议通过了 《关于公司 2021 年限制性股票激励计划（草案）及其摘要的议案》《关于公司 2021 年限制性股票激励计划实施考核管理办法的议案》《关于提请公司股东大会 授权董事会办理股权激励相关事宜的议案》等议案。公司独立董事就《2021 年 限制性股票激励计划（草案）》相关议案发表了同意的独立意见。同日，公司召 开第一届监事会第十一次会议，审议通过《关于公司 2021 年限 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 106,736,382.81, a decrease of 0.60% compared to CNY 107,382,466.51 in the same period last year[3] - Net profit attributable to shareholders increased by 102.90% to CNY 28,284,392.84 from CNY 13,940,028.65 year-on-year[3] - The net profit after deducting non-recurring gains and losses rose by 113.63% to CNY 17,505,638.85, compared to CNY 8,194,191.46 in the previous year[3] - Basic earnings per share increased by 133.33% to CNY 0.07 from CNY 0.03 year-on-year[5] - Operating profit for Q1 2025 increased to CNY 31.19 million, up 115.5% from CNY 14.50 million in Q1 2024[17] - Net profit for Q1 2025 reached CNY 27.78 million, representing a 99.5% increase from CNY 13.91 million in Q1 2024[17] - The total comprehensive income attributable to the parent company's owners for Q1 2025 was CNY 31,802,078.64, compared to CNY 13,872,575.70 in Q1 2024, representing a significant increase[18] Cash Flow - The net cash flow from operating activities was CNY 67,703,013.64, reflecting a 65.67% increase from CNY 40,865,611.68 in the same period last year[3] - Cash inflow from operating activities totaled CNY 152,074,084.77 in Q1 2025, an increase from CNY 119,226,178.01 in Q1 2024, marking a rise of 27.55%[18] - Cash outflow from operating activities was CNY 84,371,071.13 in Q1 2025, compared to CNY 78,360,566.33 in Q1 2024, which is an increase of 7.66%[18] - The net cash flow from investing activities for Q1 2025 was -CNY 27,265,973.12, a decrease from CNY 56,428,214.18 in Q1 2024[19] - Cash inflow from investing activities in Q1 2025 was CNY 584,471,684.37, while cash outflow was CNY 27,265,973.12, indicating a net cash outflow[19] - Cash flow from financing activities generated a net inflow of CNY 2,309,134.87 in Q1 2025, compared to a net outflow of -CNY 3,035,925.21 in Q1 2024[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,809,160,583.98, a 3.00% increase from CNY 1,756,516,608.11 at the end of the previous year[5] - Total liabilities increased to CNY 355.39 million, up from CNY 334.04 million year-over-year[15] - The company reported cash and cash equivalents of ¥505,600,712.38 as of March 31, 2025, an increase from ¥462,184,981.34 at the end of December 2024[13] - The ending balance of cash and cash equivalents as of Q1 2025 was CNY 505,237,993.26, up from CNY 467,109,403.98 in Q1 2024, showing an increase of 8.06%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,254[9] - The largest shareholder, JIN LI, holds 81,876,948 shares, representing 20.43% of total shares[10] - The second-largest shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd., holds 46,770,579 shares, accounting for 11.67%[10] - There are no significant changes in the shareholder structure or relationships among the top shareholders[10] Research and Development - Research and development expenses totaled CNY 12,824,415.49, accounting for 12.02% of operating revenue, a slight decrease from 12.10% in the previous year[5] - Research and development expenses for Q1 2025 were CNY 12.82 million, slightly down from CNY 12.99 million in Q1 2024[17] Other Income and Gains - The company reported a significant increase in other income to CNY 7.86 million, compared to CNY 1.57 million in the previous year[17] - Government subsidies increased year-on-year, contributing to the significant rise in net profit attributable to shareholders[7] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2025[20] Revenue Analysis - The company attributed the decline in operating revenue primarily to reduced milestone income from its UK subsidiary Vernalis (R&D) Limited, while excluding this, the group experienced an 8% year-on-year growth[7]

Financial Performance - The company's revenue for 2024 reached ¥426,986,937.69, representing a 14.99% increase compared to ¥371,324,936.81 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥51,357,102.96, up 26.13% from ¥40,718,459.76 in 2023[23]. - The net profit after deducting non-recurring gains and losses surged to ¥57,437,228.52, a significant increase of 1,563.94% from ¥3,451,870.89 in 2023[23]. - The net cash flow from operating activities for 2024 was ¥128,009,864.16, a slight increase of 2.24% from ¥125,208,580.35 in 2023[23]. - The total assets at the end of 2024 were ¥1,756,516,608.11, reflecting a 1.56% increase from ¥1,729,558,879.03 at the end of 2023[23]. - The net assets attributable to shareholders increased to ¥1,393,046,074.81, marking a 2.57% rise from ¥1,358,124,788.21 in 2023[23]. - Basic earnings per share for 2024 were ¥0.13, a 30.00% increase from ¥0.10 in 2023[24]. - The diluted earnings per share also stood at ¥0.13, consistent with the basic earnings per share[24]. - The weighted average return on net assets for 2024 was 3.74%, an increase of 0.65 percentage points from 3.09% in 2023[24]. - The company reported a significant increase in the weighted average return on net assets after deducting non-recurring gains and losses, reaching 4.18% compared to 0.26% in 2023[24]. Research and Development - The company is investing in the research and development of new drugs using structure-based drug design (SBDD) and fragment-based drug design (FBDD) methodologies[14]. - The company aims to achieve a 20% reduction in R&D costs through improved operational efficiencies and strategic partnerships[14]. - The R&D expense as a percentage of operating revenue decreased by 5.67 percentage points to 15.77%[25]. - The company reported a total R&D expenditure of ¥67,328,083.61, a decrease of 15.43% compared to the previous year[126]. - R&D expenditure accounted for 15.77% of the company's operating revenue, down from 21.44%, representing a reduction of 5.67 percentage points[126]. - The number of R&D personnel increased to 406, representing 84.06% of the total workforce, compared to 374 and 82.74% in the previous period[133]. - The average salary for R&D personnel decreased to 26.82万元 from 29.43万元 in the previous period[133]. - The company has developed a DNA-encoded compound library (DEL) with over 12 trillion small molecules, making it one of the largest in the world[134]. - The company has established a nucleic acid drug research platform with expertise in bioinformatics, nucleic acid chemistry, RNA biology, and translational research, enhancing its capabilities in RNAi technology services and siRNA/saRNA design and synthesis[141]. Market Strategy and Growth - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[14]. - The company plans to expand its market presence in Asia, targeting a 30% increase in market share over the next two years[14]. - The company has initiated discussions for potential mergers and acquisitions to enhance its product portfolio and market reach[14]. - The company is focusing on its self-developed pipeline projects, adjusting its strategy based on operational cash flow balance considerations[112]. - The company is actively developing the domestic market and has established a dedicated business development team, but faces risks from high customer concentration and potential unmet demand[153]. Technology and Innovation - The company is focusing on the development of DNA-encoded compound libraries (DEL) and high-throughput screening (HTS) technologies to enhance drug discovery efficiency[13]. - The company has established a global DEL alliance with major pharmaceutical companies to enhance drug discovery processes[35]. - The DEL technology allows for the rapid identification of novel lead compounds, even for challenging targets, and is expected to contribute significantly to new drug projects entering clinical trials in the next 5-10 years[74]. - The integration of DEL technology with other drug discovery methods like FBDD and CADD is expected to enhance the overall efficiency and effectiveness of the drug discovery process[74]. - The company has successfully utilized DEL technology to design and synthesize PROTAC molecules, contributing to advancements in the protein degradation field[84]. - The company has developed focused compound libraries to optimize compounds based on specific project requirements, resulting in faster screening speeds and lower costs compared to traditional drug chemistry optimization[82]. Risks and Challenges - The company faces risks related to new drug development failures, particularly as it targets novel molecular entities, which have a higher failure rate compared to improved or generic drugs[151]. - The company is subject to macroeconomic risks, including changes in laws and regulations in foreign markets, which could affect its global operations[156]. - The company operates in a competitive environment with increasing pressure from both domestic and international biotech firms entering the DNA-encoded library technology space[155]. - The company's revenue is heavily dependent on the R&D investment levels of its clients, primarily multinational pharmaceutical companies, which could impact its business if overall R&D spending declines[155]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not experienced any significant changes in governance arrangements or other important matters[8]. - The company did not engage in any equity transfers of new drug projects during the reporting period, indicating a focus on internal development[168]. Investment and Financial Position - The total investment during the reporting period was ¥13,210,185.75, an increase of 3.28% compared to ¥12,791,160.00 in the same period last year[194]. - The company has committed to invest ¥800,000,000.00 in the Chengdu Rongchuang Fund, holding a 40% stake[195]. - The company has recognized a loss of ¥4,575,184.11 from other non-current financial assets during the reporting period[197]. - The company has a total of 17 projects under investment in the biopharmaceutical sector, with a cumulative profit impact of -119.49[199].